Mosaic PTEN alteration in the neural crest during embryogenesis results in multiple nervous system hamartomas.
Central nervous system
Hamartomas
Mosaics
Neural crest derivatives
PTEN
Journal
Acta neuropathologica communications
ISSN: 2051-5960
Titre abrégé: Acta Neuropathol Commun
Pays: England
ID NLM: 101610673
Informations de publication
Date de publication:
03 12 2019
03 12 2019
Historique:
received:
18
09
2019
accepted:
06
11
2019
entrez:
5
12
2019
pubmed:
5
12
2019
medline:
26
9
2020
Statut:
epublish
Résumé
The contribution of mosaic alterations to tumors of the nervous system and to non-malignant neurological diseases has been unmasked thanks to the development of Next Generation Sequencing (NGS) technologies. We report here the case of a young patient without any remarkable familial medical history who was first referred at 7 years of age, for an autism spectrum disorder (ASD) of Asperger type, not associated with macrocephaly. The patient subsequently presented at 10 years of age with multiple nodular lesions located within the trigeminal, facial and acoustic nerve ganglia and at the L3 level. Histological examination of this latter lesion revealed a glioneuronal hamartoma, exhibiting heterogeneous PTEN immunoreactivity, astrocyte and endothelial cell nuclei expressing PTEN, but not ganglion cells. NGS performed on the hamartoma allowed the detection of a PTEN pathogenic variant in 30% of the reads. The presence of this variant in the DNA extracted from blood and buccal swabs in 3.5 and 11% of the NGS reads, respectively, confirmed the mosaic state of the PTEN variant. The anatomical distribution of the lesions suggests that the mutational event affecting PTEN occurred in neural crest progenitors, thus explaining the absence of macrocephaly. This report shows that mosaic alteration of PTEN may result in multiple central and peripheral nervous system hamartomas and that the presence of such alteration should be considered in patients with multiple nervous system masses, even in the absence of cardinal features of PTEN hamartoma tumor syndrome, especially macrocephaly.
Identifiants
pubmed: 31796102
doi: 10.1186/s40478-019-0841-0
pii: 10.1186/s40478-019-0841-0
pmc: PMC6892231
doi:
Substances chimiques
PTEN Phosphohydrolase
EC 3.1.3.67
PTEN protein, human
EC 3.1.3.67
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
191Références
Br J Dermatol. 2003 May;148(5):1040-6
pubmed: 12786840
Hum Mol Genet. 2000 Mar 22;9(5):765-8
pubmed: 10749983
Science. 2001 Dec 7;294(5549):2186-9
pubmed: 11691952
J Med Genet. 2000 Dec;37(12):897-904
pubmed: 11106352
Eur J Hum Genet. 2007 Jul;15(7):767-73
pubmed: 17392703
Clin Genet. 2013 Dec;84(6):593-5
pubmed: 23240978
Elife. 2014 Sep 25;3:e03696
pubmed: 25255216
PLoS One. 2014 May 08;9(5):e96531
pubmed: 24810334
Trends Genet. 2015 Jul;31(7):382-92
pubmed: 25910407
J Med Genet. 2017 Jul;54(7):471-478
pubmed: 28526761
Nat Genet. 2016 Aug;48(8):935-9
pubmed: 27322544
Dermatol Clin. 2017 Jan;35(1):51-60
pubmed: 27890237
Eur J Med Genet. 2019 Dec;62(12):103596
pubmed: 30528446
Fam Cancer. 2014 Sep;13(3):459-67
pubmed: 24609522
Endocr Relat Cancer. 2018 Aug;25(8):T121-T140
pubmed: 29792313
J Med Genet. 2018 Mar;55(3):173-180
pubmed: 29070607
Cancer Genet. 2017 Oct;216-217:79-85
pubmed: 29025599
Genet Med. 2013 Dec;15(12):1004-7
pubmed: 23619277
Am J Med Genet A. 2019 Jul;179(7):1383-1389
pubmed: 31062505
Pediatr Neurol. 2018 Oct;87:20-22
pubmed: 30249355